engleski

Adverse effects and anti-SARS-CoV-2 IgG levels after BNT162b2 vaccination in health-care workers

Background: The correlation between adverse effects (AE) after BNT162b2 vaccination and anti- SARS-CoV-2 IgG titers can be expected. The severity of AE was analyzed in correlation with sex, age, history of COVID-19 and post-vaccination anti-SARS-CoV-2 IgG levels. Methods: We included healthcare workers (HCWs), who completed a self-reported post-vaccination symptom questionnaire after the first (FVD) and the second vaccine dose (SVD) administered 3 weeks apart. The severity of AEs was scaled from 1 to 3 as mild, moderate, and severe, and summarized as local, systemic, and total symptom scores. Anti- SARS-CoV-2 IgG antibody levels were measured three weeks and one month after FVD and SVD, respectively, using an anti-SARS-CoV-2 S1 IgG immunoassay (Architect, Abbott). Results: Out of 531 HCWs (median age 42.0 years ; females 83.8%), 455 (85.7%) reported AEs after FVD and 370 (69.7%) after SVD (p<0.001). The most common symptoms after FVD and SVD, were injection site pain (78.3% vs. 58.8% ; p<0.001), headache (14.7% vs. 24.3% ; p<0.001) and fatigue (12.5% vs. 23.9% ; p<0.001). Compared to FVD, local, systemic and total symptom scores (TSS) were higher after SVD (p=0.008, p<0.001, p=0.026, respectively). TSS after FVD and SVD were weakly correlated (r=0.35, p<0.001). Higher TSS after FVD was recorded in females (p<0.001), HCWs younger than 50 years (p=0.032) and HCWs with pre-vaccination COVID-19 (p=0.042). After SVD, higher TSS was only found in females (p =0.003) while pre-vaccination COVID-19 HCWs exhibited lower TSS (p=0.031). Three weeks post-FVD and one month post-SVD, HCWs with TSS higher than 4 had higher anti-SARS-CoV-2 IgG levels (p<0.001 ; p<0.001). HCWs with systemic symptom scores higher than 2 exhibited higher anti-SARS-CoV-2 IgG after FVD (p=0.032) and SVD (p=0.005). Local symptom score higher than 2 was significantly more common in HCWs with higher IgG titer after FVD (p<0.001), but not after SVD (p=0.091). Conclusion: The adverse effects after BNT162b2 vaccination were common but not severe. HCWs with systemic AEs developed higher anti-SARS-CoV-2 IgG levels after both FVD and SVD. Local AEs were in correlation with higher IgG levels after FVD, but not after SVD. Females exhibited more post-vaccine AEs.

Anti-SARS-CoV-2 ; IgG level ; COVID-19 ; BNT162b2 ; vaccination ; health care workers

nije evidentirano